Understanding how donor immune cells affect complications in cancer treatment

DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity

NIH-funded research Hackensack University Medical Center · NIH-10818559

This study is looking at how a type of immune cell called plasmacytoid dendritic cells (pDCs) can help prevent graft-versus-host disease (GVHD) in cancer patients who have had stem cell transplants, and it aims to find ways to improve these cells to help patients feel better.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionHackensack University Medical Center NIH-funded
Lab location1 site (Hackensack, United States)
Project IDNIH-10818559 on NIH RePORTER

What this research studies

This research investigates graft-versus-host disease (GVHD), a serious complication that can occur in cancer patients after receiving stem cell transplants. It focuses on the role of plasmacytoid dendritic cells (pDCs), which are crucial for immune protection, and how their failure to reconstitute can worsen GVHD. The study uses both animal models and human samples to explore the molecular defects in pDCs caused by GVHD and how restoring these cells can improve patient outcomes. By examining the interactions between donor immune cells and the recipient's immune system, the research aims to identify potential therapeutic strategies to mitigate GVHD.

Who could benefit from this research

Good fit: Ideal candidates for this research are cancer patients who are undergoing allogeneic hematopoietic cell transplantation and are at risk for developing GVHD.

Not a fit: Patients who are not undergoing stem cell transplants or those who do not have a risk of GVHD may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatments for cancer patients undergoing stem cell transplants, reducing the incidence and severity of GVHD.

How similar studies have performed: Previous research has shown promising results in understanding the role of immune cells in GVHD, indicating that this approach has potential for success.

Where this research is happening

Hackensack, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancersneoplasm/cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.